The Former Yugoslav Republic of Macedonia
Tuberculosis profile
Population  2012 2.1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.017 (0.016–0.018) 0.82 (0.77–0.87)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 0.54 (0.24–0.97) 26 (11–46)
Incidence  (includes HIV+TB) 0.39 (0.33–0.45) 18 (16–21)
Incidence (HIV+TB only)        
Case detection, all forms (%) 89 (78–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 147 (46) Relapse 22 (71)
Smear-negative 89 (28) Treatment after failure 0 (0)
Smear-unknown / not done 6 (2) Treatment after default 0 (0)
Extrapulmonary 78 (24) Other 9 (29)
Other 0 (0)      
Total new 320   Total retreatment 31  
           
Other (history unknown) 4        
Total new and relapse 342   Total cases notified 355  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.5 1.5 1.6
Age < 15 0 23 6
Laboratories 2012
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 7.1
Drug susceptibility testing (per 5 million population) 2.4
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 95   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 84  
Retreatment 78  
TB/HIV 2012 Number (%)
TB patients with known HIV status 145 (41)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB 22  
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0 (0–2.4) 15 (4.4–35)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 5 (1–11)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 155 (81%) 26 (84%) 181
Laboratory-confirmed MDR-TB cases 0 4 4
Patients started on MDR-TB treatment     3
Financing TB control 2013
National TB programme budget (US$ millions) 1.5
% Funded domestically 8%
% Funded internationally 92%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-18 Data: www.who.int/tb/data